Scarica l'app Stockscreener
2.84
1.79%
0.05
Dopo l'orario di chiusura:
2.86
0.02
+0.70%
Precedente Chiudi:
$2.79
Aprire:
$2.64
Volume 24 ore:
29,000
Relative Volume:
0.63
Capitalizzazione di mercato:
$26.38M
Reddito:
-
Utile/perdita netta:
$-45.57M
Rapporto P/E:
-0.4508
EPS:
-6.3
Flusso di cassa netto:
$-38.56M
1 W Prestazione:
+13.60%
1M Prestazione:
+59.55%
6M Prestazione:
-19.55%
1 anno Prestazione:
-2.74%
Intervallo 1D:
$2.64
$2.8945
Intervallo di 1 settimana:
$2.31
$2.98
Portata 52W:
$1.00
$5.01
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Confronta SABS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.84 | 23.22M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SAB Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Why SAB Biotherapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
What makes SAB Biotherapeutics Inc. stock price move sharplyBreakout Confirmation Tool - Newser
How SAB Biotherapeutics Inc. stock performs during market volatilityLow Risk Trading Ideas - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Predictions - Newser
How SAB Biotherapeutics Inc. Equity Warrant stock performs during market volatility10x Potential Stocks - Newser
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyFree Predictions - Newser
Millennium Management LLC Decreases Stock Holdings in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
Northern Trust Corp Invests $43,000 in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital - Defense World
Analysts Offer Predictions for SABS Q2 Earnings - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Monday - Defense World
HC Wainwright Initiates Coverage on SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Brookline Capital Management Comments on SABS Q2 Earnings - Defense World
SABS Maintains Buy Rating by Chardan Capital with $20 Target | S - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
SAB Biotherapeutics (SABS) Receives New "Buy" Rating from Analys - GuruFocus
SAB Biotherapeutics (SABS) Receives Buy Rating and $10 Target fr - GuruFocus
Head to Head Analysis: SAB Biotherapeutics (SABS) and Its Peers - Defense World
SAB BIO (SABS) Reports Cash Decrease as Progress in T1D Therapy Advances | SABS Stock News - GuruFocus
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewswire
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Shares Purchased by Geode Capital Management LLC - Defense World
Financial Review: SAB Biotherapeutics (SABS) & The Competition - Defense World
Head-To-Head Review: SAB Biotherapeutics (SABS) versus Its Peers - Defense World
SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast - Defense World
SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
FY2025 Earnings Forecast for SABS Issued By Chardan Capital - Defense World
HC Wainwright Brokers Boost Earnings Estimates for SABS - Defense World
SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - The AM Reporter
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan - TipRanks
Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating - TipRanks
SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire
SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials - Stock Titan
SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 - TipRanks
SAB Biotherapeutics, Inc. SEC 10-K Report - TradingView
Financial Contrast: SAB Biotherapeutics (NASDAQ:SABS) versus Kiromic BioPharma (NASDAQ:KRBP) - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36 - MSN
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):